Skip to main content
SpringerLink
Log in

Prazosin concentration monitoring in the treatment of prostatic adenoma

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

In a prospective study of 32 patients with BPH treated with Minipress* (prazosin), determinations of drug plasma levels were carried out. The comparison of clinical results and serum plasma levels enabled optimalization of the dosage in long-term therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Caine, M.: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.J. Urol. 136, 1 (1986).

    PubMed  CAS  Google Scholar 

  2. Chodera, A., Herman, Z. S. (eds.). Clinical Pharmacology. PZWL, Warsaw 1986.

    Google Scholar 

  3. Dutkiewicz, S.: Treatment of prostatic adenoma with use of Minipress.Terapia i Leki, 6, 107 (1989).

    Google Scholar 

  4. Filipek, M., Dutkiewicz, S.: HPLC Method for Determination of Prazosin in Human Serum.J. Chromatogr., Biomed. Appl. Elsevier Science Publishers B. V., Amsterdam (in press).

  5. Górecki, R., Krzeski, T., Wasik, J., Borówka, A.: Evaluation of the effectiveness of Minipress (prazosin, Pfizer Firm) in treatment of BPH.Pol. Tyg. Lek. (in press).

  6. Kuźnik, Z., Dutkiewicz, S.: Evaluation of the effectiveness of the preparation Minipress (prazosin hydrochloride) manufactured by Pfizer Firm, in the therapy of BPH.Urol. Pol., 42, 82 (1989).

    Google Scholar 

  7. Long, J. W.: Clinical management—prescription of drugs. Prazosin. Harper and Row Publishers, Philadelphia 1984.

    Google Scholar 

  8. Parzen, E.: The role of spectral analysis in time series analysis. Clearinhouse Document, London 1965.

  9. Sznajderman, M.: Prazosin—the place in therapy.Terapia i Leki, 10, 197 (1988).

    Google Scholar 

  10. Vincent, J., Meredith, P. A., Reid, J. L., Elliot, H. L., Rubin, P. C.: Pharmacokinetics of prazosin.Clin. Pharmacokinetics (Reprint),10, 144 (1985).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Institute of Clinical Medicine, Ministry of Internal Affairs, Warsaw, Poland

    S. Dutkiewicz

  2. Laboratory of Clinical Pharmacokinetics, Center for the Child's Health, Warsaw, Poland

    M. Filipek

Authors
  1. S. Dutkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Filipek
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Minipress, developed by Pfizer Inc. (USA), was employed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dutkiewicz, S., Filipek, M. Prazosin concentration monitoring in the treatment of prostatic adenoma. International Urology and Nephrology 23, 143–150 (1991). https://doi.org/10.1007/BF02549711

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02549711

Keywords

Search

Navigation